Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 27 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Gufic BioSciences Ltd

About the Company - Gufic BioSciences Ltd

Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 779.16 Cr. and Equity Capital is Rs. 9.69 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069info@guficbio.com
http://www.gufic.com
Management
NamePosition Held
Mr. Jayesh P ChoksiChairman & Managing Director
Mr. Pranav J ChoksiWholeTime Director & CEO
Mr. Pankaj J GandhiWhole Time Director
Mr. Dilip B GhoshWhole Time Director
Dr. Balram H SinghNon Exe.Non Ind.Director
Mr. Shreyas K PatelIndependent Director
Mr. Shrirang V VaidyaIndependent Director
Dr. Anu S AuoraIndependent Director
Dr. Rabi N SahooIndependent Director
Mr. Gopal M DaptariIndependent Director

Basic Stock Data of Gufic BioSciences Ltd

Last Updated: July 26, 2024, 10:37 pm

Market Cap 3,510 Cr.
Current Price 350
High / Low387/237
Stock P/E40.7
Book Value 53.1
Dividend Yield0.03 %
ROCE16.9 %
ROE19.6 %
Face Value 1.00
PEG Ratio1.69

Data Source: screener.in

Gufic BioSciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales128167132251194172162165175177173195215
Expenses99139108205158139130132142143141160176
Operating Profit29272446363333333334323539
OPM %23%16%18%18%18%19%20%20%19%19%19%18%18%
Other Income2011020011110
Interest4431211122344
Depreciation5344445456644
Profit before tax23201742302926282727242831
Tax %25%24%25%25%23%27%23%26%26%25%24%26%25%
Net Profit17151331232120212020182123
EPS in Rs2.231.991.653.222.412.172.092.172.082.101.872.132.39

Last Updated: July 10, 2024, 5:38 pm

Gufic BioSciences Ltd Quarterly Chart

Gufic BioSciences Ltd Profit & Loss

Last Updated: July 10, 2024, 5:38 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales8198121148201245306351379488779691785
Expenses7487109134181222267305327404631556641
Operating Profit7111214202339465284148135143
OPM %9%11%10%10%10%9%13%13%14%17%19%20%18%
Other Income0011114464332
Interest34446691014145815
Depreciation222444451416192219
Profit before tax3567101430353058127107112
Tax %49%37%32%36%29%37%45%38%25%23%24%25%
Net Profit23447916222344968084
EPS in Rs0.200.430.550.540.951.172.132.822.925.689.898.228.61
Dividend Payout %25%12%9%9%5%4%2%2%2%2%1%1%

Gufic BioSciences Ltd Profit & Loss Yearly Chart

Gufic BioSciences Ltd Growth

Compounded Sales Growth
10 Years:21%
5 Years:18%
3 Years:18%
TTM:17%
Compounded Profit Growth
10 Years:35%
5 Years:32%
3 Years:25%
TTM:8%
Stock Price CAGR
10 Years:42%
5 Years:42%
3 Years:24%
1 Year:46%
Return on Equity
10 Years:27%
5 Years:27%
3 Years:27%
Last Year:20%

Last Updated: July 25, 2024, 5:10 am

Gufic BioSciences Ltd Balance Sheet

Last Updated: July 10, 2024, 5:38 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital888888881010101010
Reserves1215181926304668120164259338381
Borrowings20353333435780981266264334359
Other Liabilities343252677584104106152157188179220
Total Liabilities7490111127152178238280408392521861969
Fixed Assets182730252222232483100115160165
CWIP130000210311341170258
Investments0000000000011
Other Assets556081102130156213245294279365531546
Total Assets7490111127152178238280408392521861969

Gufic BioSciences Ltd Reserves and Borrowings Chart

Gufic BioSciences Ltd Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 51111-4-4-554787106-27-7
Cash from Investing Activity -13-3-2-1-5-9-13-43-7-95-191-102
Cash from Financing Activity 8-7-557148-4-79-623482
Net Cash Flow014-0-11-002517-27

Gufic BioSciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days10175858210278971071039371109
Inventory Days137143144165180190238190249138102202
Days Payable180144176223188132192157238162125143
Cash Conversion Cycle58745425941361431411146948167
Working Capital Days8271644876841091281108058136
ROCE %15%18%17%18%24%24%33%30%21%29%46%23%

Gufic BioSciences Ltd Financial Efficiency Indicators Chart

Gufic BioSciences Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters65.13%75.48%75.48%75.48%75.00%75.00%75.00%75.00%75.00%75.00%72.51%72.51%
FIIs0.14%1.52%1.69%1.51%1.38%0.06%0.16%0.72%0.70%0.72%0.47%0.12%
DIIs3.24%2.13%1.19%1.12%1.13%1.16%1.16%1.16%1.16%1.63%1.72%2.20%
Public31.49%20.87%21.64%21.89%22.49%23.76%23.67%23.12%23.12%22.64%25.29%25.17%
No. of Shareholders43,88335,13534,58038,14440,12041,37640,56238,90238,62436,55734,42434,695

Gufic BioSciences Ltd Shareholding Pattern Chart

No. of Gufic BioSciences Ltd Shareholders

Gufic BioSciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Healthcare Opportunities Fund1,000,0001.3226.0823,0732024-07-244234.07%
Quant Business Cycle Fund438,6031.7811.4423,0732024-07-241800.94%
Motilal Oswal Nifty Microcap 250 Index Fund23,0730.130.623,0732024-07-240%
Motilal Oswal S&P BSE Healthcare ETF2470.080.0123,0732024-07-24-98.93%
Groww Nifty Total Market Index Fund530023,0732024-07-24-99.77%

Gufic BioSciences Ltd ROCE Trend

Gufic BioSciences Ltd EPS Trend

Gufic BioSciences Ltd Key Financial Ratios

MonthMar 24
FaceValue1.00
Basic EPS (Rs.)8.74
Diluted EPS (Rs.)8.74
Cash EPS (Rs.)10.29
Book Value[Excl.RevalReserv]/Share (Rs.)53.11
Book Value[Incl.RevalReserv]/Share (Rs.)53.11
Revenue From Operations / Share (Rs.)80.44
PBDIT / Share (Rs.)14.76
PBIT / Share (Rs.)13.07
PBT / Share (Rs.)11.54
Net Profit / Share (Rs.)8.59
NP After MI And SOA / Share (Rs.)8.59
PBDIT Margin (%)18.35
PBIT Margin (%)16.24
PBT Margin (%)14.33
Net Profit Margin (%)10.67
NP After MI And SOA Margin (%)10.67
Return on Networth / Equity (%)16.17
Return on Capital Employeed (%)18.18
Return On Assets (%)7.88
Long Term Debt / Equity (X)0.28
Total Debt / Equity (X)0.59
Current Ratio (X)1.61
Quick Ratio (X)1.08
Interest Coverage Ratio (X)9.64
Interest Coverage Ratio (Post Tax) (X)6.61
Enterprise Value (Cr.)3142.92
EV / Net Operating Revenue (X)3.90
EV / EBITDA (X)21.23
MarketCap / Net Operating Revenue (X)3.52
Price / BV (X)5.33
Price / Net Operating Revenue (X)3.52
EarningsYield0.03

Gufic BioSciences Ltd Profitability Ratios (%)

Gufic BioSciences Ltd Liquidity Ratios

Gufic BioSciences Ltd Liquidity Ratios (%)

Gufic BioSciences Ltd Interest Coverage Ratios (%)

Gufic BioSciences Ltd Valuation Ratios

Fair Value

Fair Value: 423.72

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 21.06% compared to the current price 350

Intrinsic Value: 526.02

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 50.29% compared to the current price 350

Last 5 Year EPS CAGR: 24.14%

*Investments are subject to market risks

Strength and Weakness of Gufic BioSciences Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 24.83%, which is a positive sign.
  2. The company has higher reserves (135.50 cr) compared to borrowings (108.17 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (359.46 cr) and profit (41.85 cr) over the years.
  1. The stock has a high average Working Capital Days of 87.17, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 93.58, which may not be favorable.

FAQ

What is the latest fair value of Gufic BioSciences Ltd?

The latest fair value of Gufic BioSciences Ltd is ₹423.72.

What is the Market Cap of Gufic BioSciences Ltd?

The Market Cap of Gufic BioSciences Ltd is 3,510 Cr..

What is the current Stock Price of Gufic BioSciences Ltd as on 27 July 2024?

The current stock price of Gufic BioSciences Ltd as on 27 July 2024 is 350.

What is the High / Low of Gufic BioSciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of Gufic BioSciences Ltd stocks is 387/237.

What is the Stock P/E of Gufic BioSciences Ltd?

The Stock P/E of Gufic BioSciences Ltd is 40.7.

What is the Book Value of Gufic BioSciences Ltd?

The Book Value of Gufic BioSciences Ltd is 53.1.

What is the Dividend Yield of Gufic BioSciences Ltd?

The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.

What is the ROCE of Gufic BioSciences Ltd?

The ROCE of Gufic BioSciences Ltd is 16.9 %.

What is the ROE of Gufic BioSciences Ltd?

The ROE of Gufic BioSciences Ltd is 19.6 %.

What is the Face Value of Gufic BioSciences Ltd?

The Face Value of Gufic BioSciences Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gufic BioSciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE